Jonathan Alspaugh

Jonathan Alspaugh

Former Chief Financial OfficeratSpyre Therapeutics· In proxies 2022–2023

Pay in FY2023+726% from the year before · Spyre Therapeutics stock +91.3% the same year

Jonathan Alspaugh was paid $8.4M in FY2023 (Dec), up 726%. Spyre Therapeutics stock rose 91.3% that year.

Pay$100 in the stock at the end of FY21 → $18
Pay is from the Summary Compensation Table of each Spyre Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Spyre TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role -6%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?